American Society of Hirudotherapy

Tissue factor pathway inhibitor in atherosclerosis.

Review published in Clinica chimica acta; international journal of clinical chemistry (2019)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentSalivary PharmacologyYuan et al. · Clinica chimica acta; international journal of clinical chemistry, 2019

Abstract

Tissue factor pathway inhibitor (TFPI) reduces the development of atherosclerosis by regulating tissue factor (TF) mediated coagulation pathway. In this review, we focus on recent findings on the inhibitory effects of TFPI on endothelial cell activation, vascular smooth muscle cell (VSMC) proliferation and migration, inflammatory cell recruitment and extracellular matrix which are associated with the development of atherosclerosis. Meanwhile, we are also concerned about the impact of TFPI levels and genetic polymorphisms on clinical atherogenesis. This article aims to explain the mechanism in inhibiting the development of atherosclerosis and clinical effects of TFPI, and provide new ideas for the clinical researches and mechanism studies of atherothrombosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAtherosclerosisHumansLipoproteins

Summary

Tissue factor pathway inhibitor (TFPI) reduces the development of atherosclerosis by regulating tissue factor (TF) mediated coagulation pathway. In this review, we focus on recent findings on the inhibitory effects of TFPI on endothelial cell activation, vascular smooth muscle cell (VSMC)...

Why This Matters for Hirudotherapy

This review examined the role of tissue factor pathway inhibitor (TFPI) in reducing atherosclerosis by regulating coagulation pathways, endothelial cell activation, vascular smooth muscle cell proliferation and migration, and inflammatory cell recruitment. The abstract discusses only the endogenous inhibitor TFPI and its impact on atherogenesis, including genetic polymorphisms and clinical effects. For the American Society of Hirudotherapy, the topic of coagulation inhibition is conceptually adjacent, but the abstract contains no mention of leeches, hirudotherapy, leech-derived compounds, or the leech secretome. Any relevance is purely indirect, as the review does not evaluate or compare exogenous anticoagulants from any source.

Citation

Tissue factor pathway inhibitor in atherosclerosis.

Yuan et al. · Clinica chimica acta; international journal of clinical chemistry, 2019

DOI

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.